Get the Stockscreener App
48.75
1.28%
-0.63
After Hours:
48.81
0.06
+0.12%
Bright Minds Biosciences Inc stock is traded at $48.75, with a volume of 80,383.
It is down -1.28% in the last 24 hours and up +23.45% over the past month.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$49.38
Open:
$49.49
24h Volume:
80,383
Relative Volume:
1.38
Market Cap:
$343.39M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-37.00
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
+15.41%
1M Performance:
+23.45%
6M Performance:
+34.48%
1Y Performance:
+3,800%
1-Day Range:
$47.81
$49.49
1-Week Range:
$39.70
$49.49
52-Week Range:
$0.94
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
48.75 | 298.93M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by BTIG Research - MarketBeat
Is Bright Minds Biosciences Inc. stock reversal real or fake2025 Market Sentiment & Reliable Intraday Trade Alerts - Newser
Ranking Bright Minds Biosciences Inc. among high performing stocks via toolsPortfolio Performance Report & AI Forecasted Entry/Exit Points - Newser
Trend analysis for Bright Minds Biosciences Inc. this weekJuly 2025 Highlights & AI Driven Price Predictions - Newser
What does recent volatility data suggest for Bright Minds Biosciences Inc.Earnings Miss & Advanced Technical Signal Analysis - Newser
Applying big data sentiment scoring on Bright Minds Biosciences Inc.Stop Loss & Fast Momentum Entry Tips - Newser
Bright Minds Biosciences Inc. stock trendline breakdown2025 Market WrapUp & Accurate Buy Signal Alerts - Newser
Will earnings trigger a reversal in Bright Minds Biosciences Inc.2025 Dividend Review & Safe Capital Investment Plans - Newser
What MACD and RSI say about Bright Minds Biosciences Inc.2025 Year in Review & Expert-Curated Trade Recommendations - Newser
Why Bright Minds Biosciences Inc. is moving todayQuarterly Market Summary & Stepwise Swing Trade Plans - Newser
Price action breakdown for Bright Minds Biosciences Inc.July 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Best data tools to analyze Bright Minds Biosciences Inc. stockWeekly Earnings Recap & AI Powered Buy/Sell Recommendations - Newser
Bright Minds Biosciences Inc.’s volatility index tracking explainedJobs Report & AI Driven Stock Reports - Newser
Will Bright Minds Biosciences Inc. bounce back from current supportWeekly Stock Recap & Technical Buy Zone Confirmations - Newser
Published on: 2025-09-12 01:01:15 - Newser
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives $81.00 Consensus PT from Brokerages - Defense World
Key metrics from Bright Minds Biosciences Inc.’s quarterly dataJuly 2025 Retail & Safe Swing Trade Setups - Newser
Short interest data insights for Bright Minds Biosciences Inc.July 2025 Closing Moves & Reliable Breakout Forecasts - Newser
Will Bright Minds Biosciences Inc. benefit from macro trendsJuly 2025 Technicals & Fast Exit Strategy with Risk Control - Newser
Intraday pattern recognizer results for Bright Minds Biosciences Inc.Market Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Volatility clustering patterns for Bright Minds Biosciences Inc.July 2025 Action & Pattern Based Trade Signal System - Newser
Is this a good reentry point in Bright Minds Biosciences Inc.July 2025 Movers & Expert Approved Momentum Ideas - Newser
Can technical indicators confirm Bright Minds Biosciences Inc.’s reversalJuly 2025 Catalysts & Advanced Technical Signal Analysis - Newser
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Analyzing net buyer seller activity in Bright Minds Biosciences Inc.Quarterly Trade Summary & Intraday High Probability Alerts - Newser
What makes Bright Minds Biosciences Inc. stock price move sharply2025 Short Interest & High Return Trade Guides - Newser
Analyzing Bright Minds Biosciences Inc. with risk reward ratio chartsEarnings Growth Summary & Technical Buy Zone Confirmations - Newser
What momentum shifts mean for Bright Minds Biosciences Inc.July 2025 Analyst Calls & Low Volatility Stock Suggestions - Newser
Bright Minds Biosciences Inc. $DRUG Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Bright Minds Biosciences Inc. recovery potential after sell offEarnings Miss & High Conviction Investment Ideas - Newser
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):